Screener
Rapport Therapeutics, Inc. RAPP Other Costs — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For The Six Months Ended June 30, 2026 | For The Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | — | $20,000 | — |
| Operating expenses | ||||
| Research and development | 51,414 | 22,680 | 84,130 | 42,252 |
| Selling, general and administrative | 9,392 | 6,816 | 20,891 | 14,352 |
| Total operating expenses | 60,806 | 29,496 | 105,021 | 56,604 |
| Loss from operations | (60,806) | (29,496) | (85,021) | (56,604) |
| Other income: | ||||
| Interest income | 4,191 | 2,764 | 8,549 | 5,809 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s other costs — research and development expense?
- Rapport Therapeutics, Inc. (RAPP) reported other costs — research and development expense of $1.82M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s other costs — research and development expense changed year-over-year?
- Rapport Therapeutics, Inc.'s other costs — research and development expense increased by 13.2% year-over-year, from $1.61M to $1.82M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s other costs — research and development expense?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s other costs — research and development expense has grown at a 109.4% compound annual growth rate (CAGR), from $1.52M to $6.68M.
- What does other costs — research and development expense mean?
- This metric represents the total expenditures allocated to the discovery and clinical development of novel small-molecule therapeutics targeting central nervous system disorders. It captures the costs associated with mapping neuronal receptor complexes and advancing pipeline candidates through various stages of clinical trials. As a primary driver of long-term value for a clinical-stage biopharmaceutical company, this figure reflects the intensity of investment in scientific innovation and future product commercialization.
Ask your AI about Rapport Therapeutics, Inc.'s other costs — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude